28.50
+2.21(+8.41%)
Currency In USD
Address
Gooimeer 2-35
Naarden, 1411 DC
Netherlands
Phone
31 35 206 2971
Sector
Healthcare
Industry
Biotechnology
Employees
68
First IPO Date
February 09, 2021
| Name | Title | Pay | Year Born |
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | Chief Executive Officer, President, Executive Board Member & Director | 1.12M | 1956 |
| Ms. Juliette Audet M.B.A., M.Sc. | Chief Strategy & Business Officer | 653,039 | 1987 |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board & Director | 813,077 | 1954 |
| Mr. Mayur Amrat Somaiya | Chief Financial Officer | 841,238 | 1974 |
| Mr. Douglas F. Kling | Chief Operating Officer | 913,742 | 1973 |
| Mr. Matthew Philippe | Executive Vice President &Head of Investor Relations | 0 | N/A |
| Ms. Louise Kooij | Chief Accounting Officer | 0 | 1976 |
| Dr. Marc Ditmarsch M.D. | Chief Development Officer | 0 | 1967 |
| Ms. Maryellen McQuade | Chief People Officer | 0 | N/A |
| Mr. Bob Rambo | Executive Vice President of Marketing | 0 | N/A |
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.